Document:

Converted by EDGARwiz

EXHIBIT 10.1

DARTMOUTH - PHYTOMEDICAL TECHNOLOGIES RESEARCH AGREEMENT

This Agreement, effective this 1st day of June 2007, between

TRUSTEES OF DARTMOUTH COLLEGE, a non-profit educational institution existing under the laws of the State of New Hampshire, and being located at Hanover, New Hampshire 03755, hereinafter called Dartmouth, and PHYTOMEDICAL TECHNOLOGIES INC., a corporation of the State of Nevada, with a principal place of business at 100 Overlook Dr., 2nd Flr., Princeton, NJ 08540, hereinafter called PHYTOMEDICAL. 

WHEREAS, Dartmouth under the direction of Principal Investigator Gordon Gribble, Ph.D., wishes to further research and development for anti-tumor bis-acridines, as described in the Research Plan (Attachment B); and

WHEREAS, PHYTOMEDICAL wishes to sponsor such research under the terms and conditions hereinafter set forth; 

NOW THEREFORE, in consideration of the premises and the faithful performance of the covenants herein contained, IT IS AGREED:

Section 1.  Affiliate.  "Affiliate" shall mean a legal entity at least 50% of the voting stock of which is owned directly or indirectly by PHYTOMEDICAL.

Section 2.  Agreement.  "Agreement" shall mean this Research Agreement.

Section 3.  Effective Date.  "Effective Date" shall mean the date first written above and shall be the Effective Date of this Agreement.

Section 4. Dartmouth Pre-existing Know-How.  “Dartmouth Pre-existing Know-How” shall mean the ideas, methods, inventions, improvements, characterization and techniques developed by Dartmouth prior to this agreement relating the US Patent 6,187,787 issued February 13, 2001 to Dartmouth College; "Bis(9-Aminoacridine) DNA Intercalating Agents Having Antitumor Activity.")

Section 5.  Dartmouth Know-How.  "Dartmouth Know-How" shall mean the ideas, methods, inventions, improvements, characterization and techniques hereinafter developed by Dartmouth relating to anti-tumor bis-acridines, pursuant to the terms of this agreement. 

Section 6.   Dartmouth Pre-existing Patent Rights.  “Dartmouth Pre-existing Patent Rights” shall mean the US Patent 6,187,787 issued February 13, 2001 to Dartmouth College; "Bis (9-Aminoacridine) DNA Intercalating Agents Having Antitumor Activity").

Section 7.  Dartmouth Patent Rights.  "Dartmouth Patent Rights" shall mean any United States or foreign patent applications and any United States Patent issuing from such applications, and any continuations, continuations-in-part, divisions, reissues, reexaminations or extensions thereof, owned or assignable to Dartmouth, containing one or more claims based upon Dartmouth Know–How.

Section 8.  Joint Patent Rights.  "Joint Patent Rights" shall mean any United States or foreign patent applications and any United States Patent issuing from such applications, and any continuations, continuations-in-part, divisions, reissues, reexaminations or extensions thereof, owned or assignable to Dartmouth and PHYTOMEDICAL, containing one or more claims based upon joint inventions.  

Section 9.  Contract Period.  The "Contract Period" shall mean the period commencing on the Effective Date and ending one year from such Effective Date.

Section 10.  Research Support.  PHYTOMEDICAL shall provide research support to Dartmouth for laboratory research at a level of $45,500 for the Contract Period in accordance with the attached budget, which makes up 

Attachment A, and the attached Research Plan which makes up Attachment B.   Dartmouth shall have the flexibility to rebudget the funds as necessary during the Contract Period so as to provide the Principal Investigator the opportunity to use the funds as he deems most reasonable, provided that the funds are used within the scope of the Research Plan.  Dartmouth shall use reasonable efforts to perform the research as described in the Research Plan.

Section 11.  Inventions.  All inventions arising during the conduct of the Research Plan, conceived solely by Dartmouth inventors, shall be assigned to Dartmouth, and all inventions conceived solely by the PHYTOMEDICAL inventors shall be assigned to PHYTOMEDICAL.  For inventions that are conceived jointly by Dartmouth and PHYTOMEDICAL inventors, Dartmouth and PHYTOMEDICAL will hold joint title.

Section 12.  License Rights to Pre-existing Patent Rights.  Dartmouth hereby grants PHYTOMEDICAL the option of a world-wide, royalty-bearing exclusive license under Dartmouth Pre-existing Patent Rights and Dartmouth Pre-existing Know-How to make, have made, use and sell in the field of oncology-,) the products embodying or produced through the use of Dartmouth’s Patent Rights, at reasonable terms and condition as the parties may agree.  PHYTOMEDICAL shall have forty five (45) days after the expiration of the Contract Period to exercise this option.  If within ninety (90) days from the option exercise after good faith negotiations parties fail to reach an agreement on the license terms, or if PHYTOMEDICAL decides to forgo the option, Dartmouth shall be free to offer commercial license rights to any third party or to dispose of its inventions or other rights resulting therefrom in any other way it deems appropriate.

Section 13.  Patents and Patent Expenses for Pre-existing Patent Rights.  PHYTOMEDICAL will reimburse Dartmouth for all costs associated with obtaining and maintaining Dartmouth Pre-existing Patent Rights, which are to date: $12,578.02.  Provided, however, if PHYTOMEDICAL decides not to license Dartmouth Pre-existing Patent Rights, PHYTOMEDICAL shall have no obligation to reimburse Dartmouth for such costs and in such event the option granted under Section 12 to PHYTOMEDICAL by Dartmouth shall lapse in respect to the Dartmouth Pre-existing Patent Rights for which PHYTOMEDICAL declines to reimburse the cost to Dartmouth.

  Section 14.  License Rights to Patent Rights.  Dartmouth hereby grants PHYTOMEDICAL the option of a world-wide, royalty-bearing exclusive license under Dartmouth Patent Rights, and Dartmouth Know-How, and Joint Patent Rights, to make, have made, use and sell in the field of oncology) the products embodying or produced through the use of Dartmouth's or joint inventions, at reasonable terms and conditions as the parties may agree, which, in the case of ongoing royalties, will not exceed 3% of net sales, and, in the case of a one time license fee, not to exceed $15,000;  except to the extent of any rights required to be granted to the Government of the United States of America pursuant to 35 U.S.C. §§200-211.  PHYTOMEDICAL shall have forty five (45) days after the expiration of the Contract Period to exercise this option.  If within ninety (90) days from the option exercise after good faith negotiations parties fail to reach an agreement on the license terms, or if PHYTOMEDICAL decides to forgo the option, Dartmouth shall be free to offer commercial license rights to any third party or to dispose of its inventions or other rights resulting therefrom in any other way it deems appropriate.

Section 15. Patents and Patent Expenses for Patent Rights. PHYTOMEDICAL will reimburse Dartmouth for all costs associated with obtaining and maintaining Dartmouth Patent Rights.  Provided, however, if PHYTOMEDICAL decides that it is not appropriate to apply for Dartmouth Patent Rights, PHYTOMEDICAL shall have no obligation to reimburse Dartmouth for such costs and in such event the option granted under Section 14 to PHYTOMEDICAL by Dartmouth shall lapse in respect to the Dartmouth Patent Rights for which PHYTOMEDICAL declines to reimburse the cost to Dartmouth.  Dartmouth shall also have the right to obtain patent protection on its own and at its own expense for Joint Patent Rights in the names of Dartmouth and PHYTOMEDICAL in case PHYTOMEDICAL decides not to support such filings, in which event the option granted under Section 14 to PHYTOMEDICAL by Dartmouth shall lapse in respect to Dartmouth's rights under Joint Patent Rights.

 

Section 16.  Mutual Confidentiality.   PHYTOMEDICAL and Dartmouth realize that some information received by one party from the other pursuant to this Agreement shall be confidential.  Any information disclosed by either party and requiring confidential treatment shall be identified in writing as confidential or, if disclosed orally or visually, shall be summarized and confirmed in writing as confidential within 30 days of such disclosure and shall be maintained in secrecy by the receiving party. Any failure by disclosing party to identify orally disclosed information as confidential in writing shall not relieve the receiving party of its obligations under this Agreement. Each party shall use all reasonable measures to prevent disclosure of information, except to their own personnel who have a need to know 

and such information shall not be used by either party for purposes other than those contemplated by this Agreement for a period of three (3) years from the termination of the Agreement, unless or until --

(a)

said information shall become known to third parties or shall become publicly known through no fault of the receiving party, or

(b)

said information was already in the receiving party's possession prior to the disclosure of said information to the receiving party, or

(c)

said information shall be subsequently disclosed to the receiving party by a third party who is not under any obligation of confidentiality to the disclosing party, or

(d)

said information is approved for disclosure by prior written consent of the disclosing party, or

(e)

said information is required to be disclosed by court rule or governmental law or regulation, provided that the receiving party gives the disclosing party prompt notice of any  such requirement and cooperates with the disclosing party in attempting to limit such disclosure, or

(f) 

said information is proven independently developed by the receiving party without recourse or access to the information.

Section 17.  Corporate Action.  Dartmouth and PHYTOMEDICAL each represent and warrant to the other party that they have full power and authority to enter into this Agreement and carry out the transactions contemplated hereby and that all necessary corporate action had been duly taken in this regard.

   

Section 18.  Payments. For the rights and privileges granted under this Agreement, PHYTOMEDICAL shall pay to Dartmouth research support as defined in Section 8, to be paid in quarterly payments, the first to be due upon execution of this Agreement and every three month's thereafter.  Payments will be due within 30 days of PHYTOMEDICAL's receipt of Dartmouth's invoice

Section 19.  Reports.  Dartmouth shall furnish PHYTOMEDICAL with quarterly reports during the term of this Agreement summarizing the research conducted in accordance with the Research Plan.  A final written report stating the accomplishments and significant research findings shall be submitted to PHYTOMEDICAL within 90 days of the expiration of this Agreement.

 

Section 20.  Publications.  Dartmouth retains the rights to report on the results of research under this Agreement in professional journals, meetings, seminars, and the like.  Appropriate recognition of PHYTOMEDICAL's support will be included in all such reports.  However, in recognition of PHYTOMEDICAL's desire for patent protection, Dartmouth shall provide PHYTOMEDICAL with the final draft of any manuscript describing studies within the pertinent field and resulting from the sponsored research at least thirty (30) days prior to publication.

Section 21.  Use of Name.  PHYTOMEDICAL shall not use and shall not permit to be used by any other person or entity the name of Dartmouth,  nor any adaptation thereof, or the name of Dartmouth's employees, in any advertising, promotional or sales literature, or for any other purpose without prior written permission of Dartmouth. Dartmouth acknowledges that PHYTOMEDICAL is a corporation having a reporting obligation under the Securities Exchange Act of 1934, as amended, which has or may have certain disclosure and filing obligations under applicable law, including but not limited to the public announcement and disclosure of this Agreement and the filing of the same with the United States Securities and Exchange Commission; it is acknowledged and agreed that such disclosure and filing shall not be deemed a violation of this Agreement.

Section 22.  Indemnity.  PHYTOMEDICAL shall defend and indemnify and hold Dartmouth its trustees, employees, officers and agents harmless for any judgments and other liabilities based upon claims or causes of action against Dartmouth or its employees which arise out of (i) the design, production, manufacture, sale, use in commerce, lease or promotion by PHYTOMEDICAL, its Affiliates and Licensees, affiliates or agents of PHYTOMEDICAL of any product, process or service relating to, or developed pursuant to, this Agreement or (ii) any other activities to be carried out pursuant to this Agreement, except to the extent that such judgments or liabilities arise in whole or in part from the gross negligence or willful misconduct of Dartmouth or its employees, 

provided that Dartmouth promptly notifies PHYTOMEDICAL of any such claim coming to its attention and that it cooperates with PHYTOMEDICAL in the defense of such claim.  If any such claims or causes of action are made, Dartmouth shall be defended by counsel to PHYTOMEDICAL, subject to Dartmouth's approval, which shall not be unreasonably withheld.

DARTMOUTH MAKES NO WARRANTIES, EXPRESS OR IMPLIED, CONCERNING THE RESULTS OF RESEARCH PERFORMED UNDER THE RESEARCH PLAN OR OF THE MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF SUCH RESEARCH OR RESULTS

Section 23.  Termination.  Performance under this Agreement may be terminated by PHYTOMEDICAL upon sixty (60) days written notice; performance may be terminated by Dartmouth if circumstances beyond its control preclude continuation of the research.  Upon termination, Dartmouth will be reimbursed as specified in Section 14 for all costs and non-cancellable commitments incurred in the performance of the research, such reimbursement not to exceed the total estimated project cost specified in Section 8.

Section 24.  Prior Obligations.  Termination of this Agreement for any reason shall not release either party from any obligation theretofore accrued.

Section 25.  Governing Law.  This Agreement shall be construed, governed, interpreted and enforced according to the laws of the State of New Hampshire.

Section 26.  Notices.  Any notice or communication required or permitted to be given by either party hereunder, shall be deemed sufficiently given, if mailed by certified mail, return receipt requested, and addressed to the party to whom notice is given as follows:

If to PHYTOMEDICAL, to:

Greg Wujek, President, CEO

PhytoMedical Technologies

100 Overlook Drive, 2nd Floor

Princeton, N.J. 08540

-------------------

If to Dartmouth, to: 

 

Alla Kan, Director

Technology Transfer Office

Dartmouth College

11 Rope Ferry Road, #6210

Hanover, New Hampshire 03755-1404

                                

Section 27.  Assignment.  This Agreement shall be binding upon and inure to the benefit of the respective successors and assigns of the parties hereto.  However, PHYTOMEDICAL may not assign this Agreement in whole or in part without the written consent of Dartmouth.

Section 28.  Entire Agreement.  This Agreement represents the entire Agreement between the parties as of the Effective Date hereof and may only be subsequently altered or modified by an instrument in writing.  This Agreement cancels and supersedes any and all prior agreements between the parties which relate to the subject matter of this Agreement. 

Section 29.  Waiver.  A failure by one of the parties to this Agreement to assert its rights for or upon any breach or default of this Agreement shall not be deemed a waiver of such rights nor shall any such waiver be implied from acceptance of any payment.  No such failure or waiver in writing by any one of the parties hereto with respect to any rights, shall extend to or affect any subsequent breach or impair any right consequent thereon.

Section 30.  Severability.  The parties agree that it is the intention of neither party to violate any public policy, statutory or common laws, and governmental or supranational regulations; that if any sentence, paragraph, clause or combination of the same is in violation of any applicable law or regulation, or is unenforceable or void for any reason whatsoever, such sentence, paragraph, clause or combinations of the same shall be inoperative and the remainder of the Agreement shall remain binding upon the parties.

Section 31.  Mediation and Arbitration.  Both parties agree that they shall attempt to resolve any dispute arising from this Agreement through mediation.  Both parties agree that at least one company employee, capable of negotiating an agreement on behalf of his company, shall, within three weeks of receipt of written notification of a dispute, meet with at least one employee of the other party who is also capable of negotiating an agreement on behalf of his company. If no agreement can be reached, both parties agree to meet again within a four week period after the initial meeting to negotiate in good faith to resolve the dispute.  If no agreement can be reached after this second meeting, both parties agree to submit the dispute to binding arbitration under the Rules of the American Arbitration Association before a single arbitrator.

Section 32.  Headings.  The headings of the paragraphs of this Agreement are inserted for convenience only and shall not constitute a part hereof.

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement, in duplicate originals, by their respective officers hereunto duly authorized, the day and year herein written.

THE TRUSTEES OF DARTMOUTH COLLEGE

 By /s/ Alla Kan

        Name:  Alla Kan

Title:  Director

Date  May 15, 2007

       

PHYTOMEDICAL TECHNOLOGIES, INC.

By /s/ Greg Wujek

Name:  Greg Wujek

Title:  President, CEO

Date  May 25, 2007

ATTACHMENT A:

					
	 
	 
	 
	Year 1

	 

	WAGES / FRINGE

	 
	 
	 

	PI - Gribble 

	 
	 
	 

	wages 

	 
	 
	 $               2,231.25 

	 

	fringe

	 
	 
	 $                  859.03 

	38.50%

	TOTAL WAGES/FRINGE

	 $               3,090.28 

	 

	wages/fringe indirects

	 
	 $                         -   

	0.00%

	 
	 
	 
	 
	 

	Asking for 1 half week

	 
	 
	 

	 
	 
	 
	 
	 

	Research Assoc B

	 
	 
	 

	wages

	 
	 
	 $             32,000.00 

	 

	fringe

	 
	 
	 $               7,840.00 

	24.50%

	TOTAL WAGES/FRINGE

	 $             39,840.00 

	 

	wages/fringe indirects

	 
	 $                         -   

	0.00%

	 
	 
	 
	 
	 

	Asking for 100%

	 
	 
	 

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	TOTAL WAGES

	 
	 $             34,231.25 

	 

	TOTAL FRINGE

	 
	 $               8,699.03 

	 

	TOTAL WAGES/FRINGE

	 
	 $             42,930.28 

	 

	TOTAL IDCS

	 
	 $                         -   

	0.00%

	 
	 
	 
	 
	 

	EQUIPMENT

	 
	 
	 

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	TOTAL EQUIPMENT

	 
	 
	 

	NO IDCS ON CAPITAL EQUIPMENT

	 $                         -   

	 

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	TRAVEL

	 
	 
	 
	 

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	TOTAL TRAVEL

	 
	 $                         -   

	 

	IDCS ON TRAVEL 

	 
	 $                         -   

	0.00%

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	MATERIALS AND SUPPLIES

	 
	 

	 
	 
	 
	 
	 

	chemicals, solvents, expendables

	 $                  569.72 

	 

					
	glassware

	 
	 
	 $                  500.00 

	 

	chromatographic 

	 
	 $                  500.00 

	 

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	TOTAL SUPPLIES

	 
	 $               1,569.72 

	 

	IDCS ON SUPPLIES

	 
	 $                         -   

	0.00%

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	OTHER

	 
	 
	 
	 

	 
	 
	 
	 
	 

	NMR & Mass Spectrometry fees

	 $               1,000.00 

	 

	TOTAL OTHER 

	 
	 $               1,000.00 

	 

	 IDCS ON OTHER 

	 
	 $                         -   

	0.00%

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	PROJECT TOTALS

	 
	 
	 

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	TOTAL  DIRECTS 

	 
	 $             45,500.00 

	 

	 
	 
	 
	 
	 

	TOTAL INDIRECTS

	 
	 $                         -   

	 

	 
	 
	 
	 
	 

	PROJECT TOTALS

	 
	 $             45,500.00 

	 

	 $                   45,500.00 

	 
	 
	 

ATTACHMENT B:

Sponsored Research Agreement with PhytoMedical Technologies

Statement of Work

“Synthesis and Testing of Novel Bis-Acridine Antitumor Compounds”

The work at Dartmouth College will involve the chemical synthesis of novel bis-acridines for cancer testing and evaluation.  Following the preparation of starting materials, the Research Associate and the Principal Investigator will design and synthesize new examples of bis-acridines that are tethered with both flexible and semi-rigid linking chains, following the initial leads published in the relevant Dartmouth patent.  The compounds will be submitted to PhytoMedical for evaluation in human cancer cell lines in vitro and in vivo.Converted by EDGARwiz

EXHIBIT 10.2

MUTUAL TERMINATION AGREEMENT

MUTUAL TERMINATION AGREEMENT (the “Agreement”), dated as of May 29, 2007, by and between PHYTOMEDICAL TECHNOLOGIES, INC., a Nevada corporation, (the “Company”), and FUSION CAPITAL FUND II, LLC, an Illinois limited liability company (the “Buyer”).

WHEREAS, the Buyer and the Company mutually desire to terminate the Common Stock Purchase Agreement dated as of July 8, 2005 by and between the Company and the Buyer (the “Purchase Agreement”).  All capitalized terms used in this Agreement that are not defined in this Agreement shall have the meanings set forth in the Purchase Agreement;

NOW THEREFORE, the Company and the Buyer hereby agree as follows:

1.

TERMINATION OF THE PURCHASE AGREEMENT.  

The Purchase Agreement, and the other Transaction Documents between the Buyer and the Company related to the Purchase Agreement (other than this Agreement, and that certain Registration Rights Agreement between the Company and Buyer dated as of July 8, 2005, the “Registration Rights Agreement”) are hereby terminated effective as of the date hereof and any and all rights, duties and obligations arising thereunder or in connection with the Purchase Agreement, and the Transaction Documents (other then the Registration Rights Agreement and this Agreement) are now and hereafter fully and finally terminated, provided, however, that (i) the representations and warranties of the Buyer and Company contained in Sections 2 and 3 of the Purchase Agreement, (ii) the indemnification provisions set forth in Section 8 of the Purchase Agreement, (iii) the agreements and covenants set forth in Section 11 of the Purchase Agreement, and (iv) the Registration Rights Agreement, shall survive such termination and shall continue in full force and effect (the “Surviving Obligations”).

2.

MUTUAL GENERAL RELEASE.  

Except as may arise under or in connection with this Agreement and the Surviving Obligations, the Company and the Buyer hereby release and forever discharge each party hereto and its predecessors, successors and assigns, employees, shareholders, partners, managing members, officers, directors, agents, subsidiaries, divisions and affiliates from any and all claims, causes of actions, suits, demands, debts, dues, accounts, bonds, covenants, contracts, agreements, judgments whatsoever in law or in equity, whether known or unknown, including, but not limited to, any claim arising out of or relating to the transactions described in the Purchase Agreement and Transaction Documents (other than the Registration Rights Agreement or the Surviving Obligations) which any party hereto had, now has or which its heirs, executors, administrators, successors or assigns, or any of them, hereafter can, shall or may have, against any party hereto or such parties predecessors, successors and assigns, employees, shareholders, partners, managing members, officers, directors, agents, subsidiaries, divisions and affiliates, for or by reason of any cause, matter or thing whatsoever, whether arising prior to, on or after the date hereof, provided, however, that (i) this Agreement, (ii) the Surviving Obligations including, but not limited to, the Registration Rights Agreement, shall continue in full force and effect as the legal, valid and binding obligation of each party thereto enforceable against each such party in accordance with its terms.

3.

MISCELLANEOUS.

(a)

Governing Law; Jurisdiction; Jury Trial.  All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of Illinois, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Illinois or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Illinois.  Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of Chicago, for the adjudication of any dispute 

hereunder or under the other Transaction Documents or in connection herewith or therewith, or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.  Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.  EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

(b)

Counterparts.  This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile signature.

(c)

Headings.  The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.

(d)

Severability.  If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction.

(e)

Notices.  Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); or (iii) one Trading Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same.  The addresses and facsimile numbers for such communications shall be:

If to the Company:

PhytoMedical Technologies, Inc.

100 Overlook Drive

Princeton, New Jersey 08540

Telephone: (800) 611-3388

Facsimile: (604) 659-5029

Attention:  Chief Financial Officer

If to the Buyer:

Fusion Capital Fund II, LLC

222 Merchandise Mart Plaza, Suite 9-112

Chicago, IL 60654

Telephone:

312-644-6644

Facsimile:

312-644-6244

Attention:

Steven G. Martin

or at such other address and/or facsimile number and/or to the attention of such other person as the recipient party has specified by written notice given to each other party three (3) Trading Days prior to the effectiveness of such change.  Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the sender's 

facsimile machine containing the time, date, and recipient facsimile number or (C) provided by a nationally recognized overnight delivery service, shall be rebuttable evidence of personal service, receipt by facsimile or receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.

(f)

Publicity; Non-Disclosure.  The Company agrees to file with the SEC a Report on Form 8-K containing the disclosure set forth on Appendix A hereto regarding this agreement by no later than 5:00 pm Eastern Time, June 4, 2007.  The Company hereby unconditionally agrees that without the prior written consent of the Buyer, the Company shall not issue any other press release or make any other public disclosure of any kind whatsoever with respect to (i) the Buyer, its employees, its managers, or any of its affiliates, (ii) the Purchase Agreement or the transactions contemplated under the Purchase Agreement, (iii) this Agreement, and (iv) the termination of the Purchase Agreement.  In addition, the Company hereby unconditionally agrees that without the prior written consent of the Buyer, the Company shall not make any other written or verbal communication of any kind whatsoever with respect to (i) the Buyer, its employees, its managers, or any of its affiliates, (ii) the Purchase Agreement or the transactions contemplated under the Purchase Agreement, (iii) this Agreement, and (iv) the termination of the Purchase Agreement.

(g)

Rule 144.  With a view to making available to the Buyer the benefits of Rule 144 promulgated under the 1933 Act or any other similar rule or regulation of the SEC that may at any time permit the Buyer to sell any of its shares of Common Stock to the public without registration ("Rule 144"), the Company agrees to fully cooperate in the prompt removal of restrictive legend from any Common Stock share certificates delivered to the Company by the Buyer provided that an opinion of Buyer’s counsel in customary form that registration is not required under the Securities Act of 1933 or similar state laws in compliance with Rule 144 is delivered together with the certificates.

(h)

Successors and Assigns.  This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns.  The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Buyer, including by merger or consolidation.  The Buyer may not assign its rights or obligations under this Agreement.

(i)

No Third Party Beneficiaries.  This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

(j)

Further Assurances.  Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement.

(k)

No Strict Construction.  The language used in this Agreement is the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

(l)

Changes to the Terms of this Agreement.  This Agreement and any provision hereof may only be amended by an instrument in writing signed by the Company and the Buyer.  The term "Agreement" and all reference thereto, as used throughout this instrument, shall mean this instrument as originally executed, or if later amended or supplemented, then as so amended or supplemented.

(m)

Failure or Indulgence Not Waiver.  No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege.

(n)

Entire Agreement.  This Agreement supersedes all other prior oral or written agreements between the Buyer, the Company, their affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Agreement, the other Transaction Documents and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein 

and therein and, except as specifically set forth herein or therein, neither the Company nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters.  The Company acknowledges and agrees that is has not relied on, in any manner whatsoever, any representations or statements, written or oral, other than as expressly set forth in this Agreement.

IN WITNESS WHEREOF, the Buyer and the Company have caused this Mutual Termination Agreement to be duly executed as of the date first written above.

THE COMPANY:

PHYTOMEDICAL TECHNOLOGIES, INC.

By: /s/ Harmel S. Rayat

Name: Harmel S. Rayat

Title: Chief Financial Officer

FUSION CAPITAL FUND II, LLC

BY: FUSION CAPITAL PARTNERS, LLC

BY: SGM HOLDINGS CORP.

By: /s/ Steven G. Martin

Name: Steven G. Martin

Title: President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}]]